Evaluation of PKU Sphere Liquid

Vitaflo International, Ltd19 enrolled

Overview

PKU Sphere Liquid is a prospective, open-label, acceptability study to evaluate PKU sphere liquid in up to 15 participants aged 3 and above for the dietary management of PKU over 31 days.

PKU Sphere Liquid is a newly-developed Food for Special Medical Purposes (FSMP) designed for the dietary management of patients with phenylketonuria (PKU). PKU sphere liquid is a vanilla flavoured, ready-to-drink, low phenylalanine protein substitute containing a blend of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, and Docosachexaenoic acid (DHA). This is a feasibility study designed to evaluate the acceptability, tolerance and adherence of children and adults consuming PKU sphere liquid. Participants will be given a four-week supply of PKU Sphere Liquid and they will be asked to complete a daily diary and short questionnaire for four weeks to record information on: adherence, gastrointestinal tolerance, palatability and how the product is used. Each participant will be on the trial for 31 days. This includes a 3-day baseline period and 28 days taking the study product. If deemed appropriate in each individual circumstance, the sponsor of the trial, Vitaflo International Ltd, will continue to supply the product free of charge at the end of the trial until available on prescription.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Phenylketonurias

Interventions

PKU sphere liquidDIETARY_SUPPLEMENT

PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.

Eligibility

Sex: ALLMin age: 3 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of PKU requiring a low protein diet and protein substitute. * Aged three (3) years and over * Already taking a minimum of one GMP based protein substitute per day or have previously taken one * Able to comply with the study protocol and take the study product, according to the opinion of the PI. * Willingly given, written, informed consent from patient or parent/guardian. * Willingly given, written assent (if appropriate). Exclusion Criteria: * Inability to comply with the study protocol, in the opinion of the investigator. * Any co-morbidity, which, in the opinion of the investigator, would preclude participation in the study. * Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and protein supplement. * Unwilling/unable to take a GMP based protein substitute. * Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period. N.B.: Women who become pregnant unexpectedly during this study will be immediately withdrawn from the study.

Locations (3)

Royal Victoria Hospital

Belfast, United Kingdom

Birmingham Children's Hospital

Birmingham, United Kingdom

Northern General Hospital

Sheffield, United Kingdom

Outcomes

Primary Outcomes

Questionnaire of self-reported adherence to the prescribed amount of study product

Assessment of participant's adherence to prescribed amount during the eight week intake of the study product

Time frame: 4 weeks

Product acceptability rated on a Likert scale by the participant after four week intake

Assessment of participant's acceptability following four week intake of the study product Scale is from 1 to 5: 1 = Loved it, 5 = Really didn't like it

Time frame: 4 weeks

Questionnaire of self-reported changes in gastrointestinal tolerance during four week intake

Assessment of participant's gastrointestinal tolerance during the four week intake of the study product

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.